{"role": "assistant", "content": null, "function_call": {"name": "get_risks", "arguments": "{\"risks\":[{\"Description\":\"Transmissibility rebounded once controls were lifted, leading to a resurgence of cases.\",\"Impact\":\"Increased cases and potential higher mortality due to relaxed controls.\",\"Mitigation\":\"Sustained implementation of controls and interventions even after initial success.\",\"Technologies\":\"Surveillance systems for early detection and reactive response.\",\"People\":\"General public, especially in areas with relaxed controls.\",\"Owner\":\"Public health authorities and government agencies.\"},{\"Description\":\"Prolonged maintenance of Non-Pharmaceutical Interventions (NPIs) and drugs until a vaccine is available.\",\"Impact\":\"Challenges in sustaining NPIs and limited effectiveness of initial vaccines.\",\"Mitigation\":\"Investment in research and development of effective vaccines and treatments for prolonged use.\",\"Technologies\":\"Vaccine development and targeted treatment options.\",\"People\":\"Healthcare professionals, researchers, and pharmaceutical companies.\",\"Owner\":\"Government health agencies, research institutions, and pharmaceutical companies.\"},{\"Description\":\"Building population immunity through epidemic without interrupting transmission completely.\",\"Impact\":\"Risk of wider spread and potential strain on healthcare systems due to increased cases.\",\"Mitigation\":\"Targeted vaccination of at-risk individuals and continuous monitoring of population immunity.\",\"Technologies\":\"Vaccine distribution and population health monitoring systems.\",\"People\":\"At-risk individuals and healthcare professionals.\",\"Owner\":\"Government health agencies and healthcare institutions.\"}]}"}}